The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck
Open accessAbstract
The transcription factor gene MYB was identified recently as an oncogene that is rearranged/duplicated in some human leukemias. Here we describe a new mechanism of activation of MYB in human cancer involving gene fusion. We show that the t(6;9)(q22–23;p23–24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB . The minimal common part of MYB deleted as the result of fusion was exon 15 including the 3′-UTR, which contains several highly conserved target sites for miR-15a/16 and miR-150 microRNAs. These microRNAs recently were shown to regulate MYB expression negatively. We suggest that deletion of these target sites may disrupt repression of MYB leading to overexpression of MYB-NFIB transcripts and protein and to activation of critical MYB targets, including genes associated with apoptosis, cell cycle control, cell growth/angiogenesis, and cell adhesion. Forced overexpression of miR-15a/16 and miR-150 in primary fusion-positive ACC cells did not significantly alter the expression of MYB as compared with leukemic cells with MYB activation/duplication. Our data indicate that the MYB-NFIB fusion is a hallmark of ACC and that deregulation of the expression of MYB and its target genes is a key oncogenic event in the pathogenesis of ACC. Our findings also suggest that the gain-of-function activity resulting from the MYB-NFIB fusion is a candidate therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Pathology and Genetics of Tumours of the Breast and Female Genital Organs
Tavassoli, F. A., & Devilee, P. (2003) · International Agency for Research on Cancer eBooks · Cited by 2,800
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
Lee, Y. S., & Dutta, A. (2007) · Genes & Development · doi:10.1101/gad.1540407 · Cited by 1,152
Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Mayr, C., Hemann, M. T., & Bartel, D. P. (2007) · Science · doi:10.1126/science.1137999 · Cited by 1,100
MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb
Xiao, C., Calado, D. P., Galler, G., Thai, T.-H., Patterson, H. C., Wang, J., Rajewsky, N., Bender, T. P., & Rajewsky, K. (2007) · Cell · doi:10.1016/j.cell.2007.07.021 · Cited by 1,042
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
MYB function in normal and cancer cells
Ramsay, R. G., & Gonda, T. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2439 · Cited by 617
GenePaint.org: an atlas of gene expression patterns in the mouse embryo
Visel, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh029 · Cited by 528 · cited 2×
“Interestingly, we previously have identified NFIB as a recurrent fusion partner to HMGA2 in benign pleomorphic salivary gland adenomas with t(9;12) translocations (6, 8).”
BackgroundThe myb gene family in cell growth, differentiation and apoptosis
Oh, I.-H., & Reddy, E. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202839 · Cited by 498 · cited 2×
“MYB plays an important role in the control of cell proliferation, apoptosis, and differentiation, is highly expressed in immature, proliferating cells, and is down-regulated as cells become more differentiated (10, 11).”
BackgroundSakura, H., Kanei-Ishii, C., Nagase, T., Nakagoshi, H., Gonda, T. J., & Ishii, S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5758 · Cited by 333
Behboudi, A., Enlund, F., Winnes, M., Andrén, Y., Nordkvist, A., Leivo, I., Flaberg, E., Szekely, L., Mäkitie, A., Grenman, R., et al. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20306 · Cited by 322
Self-citationDuplication of the MYB oncogene in T cell acute lymphoblastic leukemia
Lahortiga, I., De Keersmaecker, K., Van Vlierberghe, P., Graux, C., Cauwelier, B., Lambert, F., Mentens, N., Beverloo, H. B., Pieters, R., Speleman, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2025 · Cited by 281
Clappier, E., Cuccuini, W., Kalota, A., Crinquette, A., Cayuela, J.-M., Dik, W. A., Langerak, A. W., Montpellier, B., Nadel, B., Walrafen, P., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064683 · Cited by 280
Frierson, H. F., El-Naggar, A. K., Welsh, J. B., Sapinoso, L. M., Su, A. I., Cheng, J., Saku, T., Moskaluk, C. A., & Hampton, G. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64408-2 · Cited by 203
Zhao, H., Kalota, A., Jin, S., & Gewirtz, A. M. (2008) · Blood · doi:10.1182/blood-2008-01-136218 · Cited by 172
Lin, Y.-C., Kuo, M.-W., Yu, J., Kuo, H.-H., Lin, R., Lo, W., & Yu, A. L.-T. (2008) · Molecular Biology and Evolution · doi:10.1093/molbev/msn165 · Cited by 124
Phuchareon, J., Ohta, Y., Woo, J. M., Eisele, D. W., & Tetsu, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006040 · Cited by 105 · cited 1×
“In the absence of t(6;9)-positive, authentic ACC cell lines (23) we used primary cultured fusion-positive ACC cells.”
Dubendorff, J. W., Whittaker, L. J., Eltman, J. T., & Lipsick, J. S. (1992) · Genes & Development · doi:10.1101/gad.6.12b.2524 · Cited by 99
Persson, F., Winnes, M., Andrén, Y., Wedell, B., Dahlenfors, R., Asp, J., Mark, J., Enlund, F., & Stenman, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210961 · Cited by 75
Self-citationQian, F., Kruse, U., Lichter, P., & Sippel, A. E. (1995) · Genomics · doi:10.1006/geno.1995.1107 · Cited by 73
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster
Chung, E. Y., Dews, M., Cozma, D., Yu, D., Wentzel, E. A., Chang, T.-C., Schelter, J. M., Cleary, M. A., Mendell, J. T., & Thomas‐Tikhonenko, A. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.11.6722 · Cited by 57
Myb proteins regulate the expression of diverse target genes
Lang, G., White, J. R., Argent-Katwala, M., Allinson, C. G., & Weston, K. (2004) · Oncogene · doi:10.1038/sj.onc.1208301 · Cited by 47
Roulet, E., Armentero, M., Krey, G. D., Corthésy, B., Dreyer, C., Mermod, N., & Wahli, W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5552 · Cited by 42
Dasgupta, P., & Reddy, E. P. (1989) · PubMed · Cited by 19
Cited by
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714
Evolution of the cancer genome
Yates, L. R., & Campbell, P. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3317 · Cited by 640
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Adenoid cystic carcinoma of the head and neck – An update
Coca-Pelaz, A., Rodrigo, J. P., Bradley, P. J., Vander Poorten, V., Triantafyllou, A., Hunt, J. L., Strojan, P., Rinaldo, A., Haigentz, M., Takes, R. P., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.04.005 · Cited by 530
Metadata
- Authors
- Persson, M., Andrén, Y., Mark, J., Horlings, H. M., Persson, F., & Stenman, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-11-03
- Volume
- 106
- Issue
- 44
- Pages
- 18740-18744
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1974202442
- Cited by
- 788
- References
- 26
- FWCI
- 32.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.